Market closed · Next open: Thursday 9:30 AM ET
Last update: Nov 18, 2026, 6:18 PM ET
Vertex Pharmaceuticals Incorporated
$536.45▲ 0.42% today
Market Closed

Why Vertex Pharmaceuticals Incorporated (VRTX) stock moved

No significant move on Nov 18, 2026 (+0.4%, close-to-close). Latest notable session: Nov 4, 2026.

Latest session▲ 3.4% · Nov 4, 2026 close

Why Vertex Pharmaceuticals Incorporated (VRTX) rose 3.4% on November 4, 2026

Vertex Pharmaceuticals Incorporated (VRTX) rose 3.4% on November 4, 2026, closing at $549.04 versus $530.76 the prior session (close-to-close, from daily closes). Two days prior, VRTX reported Q3 EPS of $4.76 versus a $4.82 estimate (−1.24% miss); Q3 revenue grew 12% YoY to $3.44B, led by cystic fibrosis drugs and new launches CASGEVY and PALSONIFY. The move also coincided with a sector-wide gain: five pharma/healthcare peers (AMGN, ABBV, UNH, BMY) posted gains of +1.86% to +2.80%, suggesting a group recovery rather than a company-specific catalyst. Source: FMP price data; BestStocks detection.

Updated
Prior close
$530.76
Nov 4, 2026 close
$549.04
Change (close-to-close)
+$18.28
+3.44%
As first detected · Nov 4, 2026, 4:41 PM ET

Vertex Pharmaceuticals Incorporated (VRTX) moved +2.50% from $535.63 to $549.04 on 2026-11-04. Two days prior, VRTX reported Q3 EPS of $4.76 versus a $4.82 estimate (−1.24% miss); Q3 revenue grew 12% YoY to $3.44B, led by cystic fibrosis drugs and new launches CASGEVY and PALSONIFY. The move also coincided with a sector-wide gain: five pharma/healthcare peers (AMGN, ABBV, UNH, BMY) posted gains of +1.86% to +2.80%, suggesting a group recovery rather than a company-specific catalyst.

What to watch next: VRTX Q4 earnings, scheduled for 2026-02-11 (consensus EPS estimate $4.23), for updates on CASGEVY and PALSONIFY adoption trends.

Source: FMP price data; BestStocks detection · percentages in this note are as captured at detection; the confirmed close-to-close move is shown above.

Earlier sessions that moved VRTX

  1. −4.0%Vertex Pharmaceuticals reported Q3 adjusted EPS of $4.76, missing the Zacks consensus estimate of $4.92, according to the web catalyst.
  2. +3.5%We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
  3. +2.5%Vertex appoints Daniel Brennan, 35-year healthcare finance veteran, as independent board director.
  4. −4.3%A Motley Fool comparison (published 2026-10-13) contrasts Vertex's cystic fibrosis dominance and diversification efforts against Moderna's mRNA expansion into RSV and oncology, but this is a retrospective ranking piece rather than a company-specific event.
  5. −3.1%We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found.

Vertex Pharmaceuticals Incorporated (VRTX) shares rose 0.4% to $536.45 as of November 19, 2026, a slight gain from the prior close of $534.20. BestStocks flagged the session as a major change for VRTX. Below, we break down what changed for VRTX, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

VRTX climbed 0.4% to $536.45

Vertex Pharmaceuticals Incorporated (VRTX) filed its 10-Q on November 3, 2026. VRTX earnings report on February 11, 2027 (date not yet confirmed).

This summary describes the catalyst and move as first detected on Nov 3, 2026, 4:45 PM EST; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
Sector-Wide MoveWeak confidence
Rel. volume
1.0×
Normal
Vs peers
Top 1 of 7 peers
Outperforming
Market cap
$136.0B
NASDAQ Global Select
Analyst target
$579
+8.0% vs price
Price chart
Nov 18
Not enough price data.
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Vertex Pharmaceuticals Incorporated investors

For Vertex Pharmaceuticals Incorporated investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 0.4% session move; Positive price momentum. Weighing against that: Vertex Pharmaceuticals declined 2.09% to $496.42 in early trading with no material catalyst evident in real-time news; New SEC filing — review for material disclosures. Because peers moved similarly, the shift looks more macro- or sector-driven than a change in VRTX's fundamentals. Wall Street's consensus price target sits at $579.29, implying +8.0% upside from $536.45. BestStocks rates the overall signal quality weak (36/100). With earnings roughly 84 days out, the next report is the most likely near-term test of the move.

VRTX price reaction

VRTX last traded at $536.45, up $2.25 (+0.42%) from the previous close of $534.20. The session traded on 1.0× average volume (normal), so participation was unremarkable. Its healthcare peer group moved a median -2.3% over the same stretch, leaving VRTX ahead of the group by 2.8 points.

Bullish and bearish analyst opinions on Vertex Pharmaceuticals Incorporated (VRTX)

The consensus analyst price target on Vertex Pharmaceuticals Incorporated (VRTX) is $579.29, 8.0% above the recent $536.45. Over the past 90 days analysts logged 0 upgrades, 13 maintains, and 0 downgrades. Here is how the bullish and bearish cases on VRTX line up.

The bullish case

  • Wall Street's consensus price target of $579.29 implies +8.0% upside from $536.45.
  • The Street's most bullish target is $665.00 (+24.0%).
  • Positive 0.4% session move.
  • Positive price momentum.

The bearish case

  • The most bearish analyst target is $350.00 (-34.8%).
  • Vertex Pharmaceuticals declined 2.09% to $496.42 in early trading with no material catalyst evident in real-time news.
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Nov 18, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $579+8.0%
= 13 maintains
Barclays maintained Overweight · 2026-11-04
SEC filings watch
No recent filings
Peer context
VRTX+0.4%
LLY-2.3%
UNH-10.2%
JNJ-2.2%
PFE-1.4%
ABBV-2.3%

Previous notable changes for VRTX

Valuation2026-11-03via Benzinga ↗
Vertex Pharmaceuticals reported Q3 adjusted EPS of $4.76, missing the Zacks consensus estimate of $4.92, according to the web catalyst. Despite revenue beating expectations at $3.44 billion (+12% YoY) and analysts raising forecasts post-earnings (Benzinga), the EPS miss and higher operating/integration costs from the $9.0 billion Crinetics Pharmaceuticals acquisition triggered selling pressure. Stock down 3.10% to $536.02 on elevated volume of 2.81x historical average.
Filings2026-11-02
Vertex Pharmaceuticals Incorporated (VRTX) filed a new 8-K on November 2, 2026. The filing content was not disclosed in available records.
News2026-10-23
Vertex's Phase 3 RAINIER trial for povetacicept in IgA Nephropathy showed best-in-class potential, published in NEJM.
News2026-10-20
Vertex appoints Daniel Brennan, 35-year healthcare finance veteran, as independent board director.
Upcoming catalysts & outlook
Next earnings
2027-02-11 (est.)
in 84 days
Thesis shift
Neutral / Mixed
bullish signal
Risk level
Medium
from change events

Frequently asked questions about VRTX

Why did Vertex Pharmaceuticals Incorporated (VRTX) stock move?

Vertex Pharmaceuticals Incorporated (VRTX) rose 3.4% on November 4, 2026, closing at $549.04 versus $530.76 the prior session (close-to-close, from daily closes). Two days prior, VRTX reported Q3 EPS of $4.76 versus a $4.82 estimate (−1.24% miss); Q3 revenue grew 12% YoY to $3.44B, led by cystic fibrosis drugs and new launches CASGEVY and PALSONIFY. The move also coincided with a sector-wide gain: five pharma/healthcare peers (AMGN, ABBV, UNH, BMY) posted gains of +1.86% to +2.80%, suggesting a group recovery rather than a company-specific catalyst. Source: FMP price data; BestStocks detection.

How much did VRTX stock rise?

VRTX gained 0.42% ($2.25) versus the prior close of $534.20, last trading at $536.45 on 1.0× average volume.

When is Vertex Pharmaceuticals Incorporated's next earnings date?

VRTX's next earnings report is estimated for 2027-02-11 — about 84 days away.

What is the analyst price target for VRTX?

The consensus analyst price target for VRTX is $579.29, about 8.0% above the current $536.45. Over the past 90 days, analysts recorded 0 upgrades, 13 maintains, and 0 downgrades.

Is the VRTX move company-specific or sector-wide?

BestStocks classifies it as a sector-wide move: the peer group moved a median -2.3% against VRTX's +0.4%. VRTX ranks top 1 of 7 peers.

How BestStocks tracks VRTX

This page is generated automatically by BestStocks' change-detection system after its price and volume cleared VRTX-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for VRTX, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 19, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataSEC EDGAR filingsFMP earnings & estimatesAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.